Targeting complement factor H for treatment of diseases
AssigneesMUSC Foundation for Research Development, The Regents of the University of Colorado, a body corporate
InventorsGary Gilkeson, Stephen Tomlinson, V. Michael Holers, Baerbel Rohrer
Life of this patent
Estimating the term…
Abstract
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
Claims25
A complement receptor 2 (CR2)-factor H (FH) molecule comprising:
- a) a CR2 portion comprising a CR2 or fragment thereof, and
- b) an FH portion comprising an FH, or a biologically active fragment thereof, capable of inhibiting activation of the alternative complement pathway,
- wherein the CR2-FH molecule is capable of binding to a CR2 ligand, and
- wherein the CR2-FH molecule is capable of inhibiting activation of the alternative complement pathway.
Dependencies are inferred from the claim text.